NCT04179630

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

A Phase 1, Single-center, Open Label, Parallel Group Study to Evaluate the Pharmacokinetics, Safety & Tolerability of a Single Dose of Aldafermin (NGM282) in Subjects With Impaired Renal Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: NGM Biopharmaceuticals, Inc · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This is a single-center evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Renal Function.

Conditions

• Impaired Renal Function

Interventions

Type	Name	Description
BIOLOGICAL	Aldafermin (NGM282)	Single 3 mg dose

Timeline

• Start date: 2019-11-08
• Primary completion: 2019-12-04
• Completion: 2019-12-14
• First posted: 2019-11-27
• Last updated: 2020-04-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study